Novartis boosts business
2012 was an eventful year for Swiss pharma outfit Novartis, which is also reflected in both the bottom and top lines of the company’s financial report for the first quarter of 2013 in spite of the effects from patent expirations.
by Leonora Beck
In the first quarter of the year the pharmaceutical company Novartis secured no less than 8 regulatory approvals. Meanwhile, sales and turnover grew compared with the same period last year.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75)
